Cimetidine enhances cisplatin toxicity in mice

Robert T Dorr, Michelle J. Soble

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The combination of the histamine H2 antagonist cimetidine (CMT) and the anticancer agent cisplatin (CDDP) was studied in normal and tumorbearing mice. CMT doses of 100 mg/kg produced no alteration in the survival of DBA/2J mice bearing P-388 leukemia treated with CDDP doses of 3 mg/kg or 6 mg/kg. In these groups, the median survival was 13 days and 16 days, respectively, compared to 10 days in untreated controls. However, when adult CD-1 mice were given higher but nonlethal CDDP doses of 10, 15, or 18 mg/kg, the addition of CMT significantly increased CDDP lethality (P<0.05 by Wilcoxon analysis). For the 3 groups, CMT-inhanced lethality occurred in 10% of mice given 10 mg/kg CDDP, 80% of mice given 15 mg/kg, and 100% of mice given 18 mg/kg CDDP. Thus, CMT can acutely alter CDDP toxicity without affecting antitumor efficacy in mice.

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalJournal of Cancer Research and Clinical Oncology
Volume114
Issue number1
DOIs
StatePublished - Feb 1988

Fingerprint

Cimetidine
Cisplatin
Histamine H2 Antagonists
Inbred DBA Mouse
Antineoplastic Agents
Leukemia

Keywords

  • Cimetidine
  • Cisplatin
  • Drug interaction
  • Mouse

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cimetidine enhances cisplatin toxicity in mice. / Dorr, Robert T; Soble, Michelle J.

In: Journal of Cancer Research and Clinical Oncology, Vol. 114, No. 1, 02.1988, p. 1-2.

Research output: Contribution to journalArticle

@article{8580c648e9d1444380dfaf372f897da0,
title = "Cimetidine enhances cisplatin toxicity in mice",
abstract = "The combination of the histamine H2 antagonist cimetidine (CMT) and the anticancer agent cisplatin (CDDP) was studied in normal and tumorbearing mice. CMT doses of 100 mg/kg produced no alteration in the survival of DBA/2J mice bearing P-388 leukemia treated with CDDP doses of 3 mg/kg or 6 mg/kg. In these groups, the median survival was 13 days and 16 days, respectively, compared to 10 days in untreated controls. However, when adult CD-1 mice were given higher but nonlethal CDDP doses of 10, 15, or 18 mg/kg, the addition of CMT significantly increased CDDP lethality (P<0.05 by Wilcoxon analysis). For the 3 groups, CMT-inhanced lethality occurred in 10{\%} of mice given 10 mg/kg CDDP, 80{\%} of mice given 15 mg/kg, and 100{\%} of mice given 18 mg/kg CDDP. Thus, CMT can acutely alter CDDP toxicity without affecting antitumor efficacy in mice.",
keywords = "Cimetidine, Cisplatin, Drug interaction, Mouse",
author = "Dorr, {Robert T} and Soble, {Michelle J.}",
year = "1988",
month = "2",
doi = "10.1007/BF00390477",
language = "English (US)",
volume = "114",
pages = "1--2",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Cimetidine enhances cisplatin toxicity in mice

AU - Dorr, Robert T

AU - Soble, Michelle J.

PY - 1988/2

Y1 - 1988/2

N2 - The combination of the histamine H2 antagonist cimetidine (CMT) and the anticancer agent cisplatin (CDDP) was studied in normal and tumorbearing mice. CMT doses of 100 mg/kg produced no alteration in the survival of DBA/2J mice bearing P-388 leukemia treated with CDDP doses of 3 mg/kg or 6 mg/kg. In these groups, the median survival was 13 days and 16 days, respectively, compared to 10 days in untreated controls. However, when adult CD-1 mice were given higher but nonlethal CDDP doses of 10, 15, or 18 mg/kg, the addition of CMT significantly increased CDDP lethality (P<0.05 by Wilcoxon analysis). For the 3 groups, CMT-inhanced lethality occurred in 10% of mice given 10 mg/kg CDDP, 80% of mice given 15 mg/kg, and 100% of mice given 18 mg/kg CDDP. Thus, CMT can acutely alter CDDP toxicity without affecting antitumor efficacy in mice.

AB - The combination of the histamine H2 antagonist cimetidine (CMT) and the anticancer agent cisplatin (CDDP) was studied in normal and tumorbearing mice. CMT doses of 100 mg/kg produced no alteration in the survival of DBA/2J mice bearing P-388 leukemia treated with CDDP doses of 3 mg/kg or 6 mg/kg. In these groups, the median survival was 13 days and 16 days, respectively, compared to 10 days in untreated controls. However, when adult CD-1 mice were given higher but nonlethal CDDP doses of 10, 15, or 18 mg/kg, the addition of CMT significantly increased CDDP lethality (P<0.05 by Wilcoxon analysis). For the 3 groups, CMT-inhanced lethality occurred in 10% of mice given 10 mg/kg CDDP, 80% of mice given 15 mg/kg, and 100% of mice given 18 mg/kg CDDP. Thus, CMT can acutely alter CDDP toxicity without affecting antitumor efficacy in mice.

KW - Cimetidine

KW - Cisplatin

KW - Drug interaction

KW - Mouse

UR - http://www.scopus.com/inward/record.url?scp=0023870399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023870399&partnerID=8YFLogxK

U2 - 10.1007/BF00390477

DO - 10.1007/BF00390477

M3 - Article

VL - 114

SP - 1

EP - 2

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 1

ER -